Berzosertib

N/A

Report date: 2024/01/02 20:03:52
NME

Base Information

Drug NameBerzosertib
Drug Alias NameM-6620VX-970VE-822
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine-protein kinase ATR inhibitors
TargetsSerine-protein kinase ATR
Therapy Area/IndicationsBrain metastasesNeuroendocrine Carcinoma of LungSolid tumours +[32] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesItaly +[9] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesVertex Pharmaceuticals Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesMerck Healthcare Kgaa, Darmstadt, Germany, An Affiliate Of Merck Kgaa, Darmstadt, GermanyInstitut BergoniéEmd Serono Research & Development Institute Inc +[6] 
Inactive CompaniesMerck Healthcare KgaaMerck Serono (Beijing) Pharmaceutical R&D Co Ltd
Active IndicationsBrain metastasesNeuroendocrine Carcinoma of LungSolid tumours +[31] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A